About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Treatment-free Remission in Patients with Chronic Phase Chronic Myeloid Leukemia and Stable Deep Molecular Response Discontinuing Dasatinib (DASFREE)
By
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy
FEATURING
Susanne Saussele
By
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy
FEATURING
Susanne Saussele
21 views
January 2, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Related Content
AUTOPLAY
ON
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
04:16
Luke Fletcher
Efficacy and Safety of Asciminib in Ph+ CML
50:34
Scripps MD Anderson Cancer Center
The Cure of Leukemias in the Next Decade: An Optimist’s View
Feat.
H. Kantarjian
07:55
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Treatment Patterns & Clinical Outcomes …
Feat.
E. Atallah
09:51
i3 Health
MRD Testing in Leukemias: When Negativity Is a Positive Thing
Feat.
N. S. Raje
16:25
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: The New ELN Laboratory Recommendations for the Diagnosis …
Feat.
N. Cross
19:15
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: CML - Are We Doing It Right?
Feat.
J. Cortés
17:30
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Rational TKI Choice in CML
Feat.
M. Deininger
17:47
The University of Alabama at Birmingham School of Medicine
Treating CML Patients With TKI Resistance vs. TKI Intolerance
Feat.
O. Jamy
24:44
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignan…
Feat.
R. Birhiray
11:02
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Asciminib Combined With Dasatinib and Predn…
Feat.
M. Luskin
17:51
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies
Chronic GVHD: A Case-Based Discussion
Feat.
L. Perry
27:47
City of Hope
Chronic GVHD: Review Advances in Prevention, Novel Endpoints, and Ta…
Feat.
I. Amanam
03:03
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Olverembatinib (HQP1351) Overcoming Ponatin…
Feat.
E. Jabbour
08:32
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "ALLG CML13 ASCEND-CML Study - Asciminib Tre…
Feat.
D. Yeung
08:02
ASH 2022 Conference Coverage
ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclop…
Feat.
S. Holtan
18:55
International CML Foundation
iCMLf Conversations: CML Clinical Highlights of EHA 2023
Feat.
A. Hochhaus
06:26
Akriti Jain
Managing TKI AEs in CML: Thrombocytopenia, Hypertension, Pancreatic …
20:43
Indy Hematology Review
Controversies in the Management of CML in 2024
Feat.
R. Larson
09:01
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Asciminib + Imatinib, Nilotinib, or Dasatin…
Feat.
J. Cortés
